| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 0.43▼ | 0.43▼ | 0.43▼ | 0.94▼ | 2.74▼ |
| MA10 | 0.43▼ | 0.43▼ | 0.43▼ | 2.06▼ | 3.61▼ |
| MA20 | 0.43▼ | 0.43▼ | 0.43▼ | 2.69▼ | 8.57▼ |
| MA50 | 0.43▼ | 0.43▼ | 1.58▼ | 4.17▼ | 12.13▼ |
| MA100 | 0.43▼ | 1.69▼ | 2.43▼ | 8.63▼ | 10.52▼ |
| MA200 | 0.43▼ | 2.49▼ | 3.05▼ | 11.46▼ | 10.84▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.000▲ | 0.022▲ | 0.091▲ | -0.202▼ | -0.758▼ |
| RSI | 44.668▼ | 24.023▼ | 13.073▼ | 15.647▼ | 22.978▼ |
| STOCH | 30.599 | 41.281 | 65.357 | 7.720▼ | 2.073▼ |
| WILL %R | -98.540▼ | -75.000▼ | -25.862 | -98.677▼ | -99.707▼ |
| CCI | 146.453▲ | 46.065 | 59.577 | -117.262▼ | -102.723▼ |
|
Thursday, October 22, 2026 07:16 AM
EyePoint Pharmaceuticals (NASDAQ: EYPT) shares have lost roughly 80% after the Phase 3 LUCIA trial of DURAVYU missed its primary endpoint in ...
|
|
Thursday, October 22, 2026 07:15 AM
When the 2026 topline data arrived, DURAVYU did not achieve non-inferiority to on-label aflibercept in LUCIA. EyePoint has since concluded its wet AMD pivotal trials early. Levi & Korsinsky is ...
|
|
Tuesday, October 20, 2026 08:09 AM
Shares of EyePoint Pharmaceuticals (NASDAQ: EYPT) have lost roughly 80% of their value after the Company's Phase 3 LUCIA trial of ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 22/10/26 | 0.43 | 0.4388 | 0.42 | 0.4281 | 12,360,259 |
| 21/10/26 | 0.415 | 0.4382 | 0.386 | 0.43 | 31,391,881 |
| 20/10/26 | 0.421 | 0.4751 | 0.405 | 0.4052 | 50,568,837 |
| 19/10/26 | 0.5502 | 0.60 | 0.4025 | 0.44 | 182,969,374 |
| 16/10/26 | 3.14 | 3.15 | 2.9512 | 2.99 | 2,749,105 |
| 15/10/26 | 3.02 | 3.18 | 3.01 | 3.14 | 2,835,600 |
| 14/10/26 | 3.04 | 3.06 | 2.93 | 3.01 | 3,156,600 |
| 13/10/26 | 3.30 | 3.315 | 3.06 | 3.07 | 2,499,096 |
| 12/10/26 | 3.42 | 3.43 | 3.29 | 3.32 | 1,895,200 |
| 09/10/26 | 3.44 | 3.5685 | 3.38 | 3.40 | 1,938,787 |
|
|
||||
|
|
||||
|
|